<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197493</url>
  </required_header>
  <id_info>
    <org_study_id>0003</org_study_id>
    <nct_id>NCT03197493</nct_id>
  </id_info>
  <brief_title>Extension, Carbidopa-levodopa in Neovascular AMD</brief_title>
  <official_title>Extension of Protocol 002, Carbidopa-levodopa in Neovascular Extension of Protocol 002, Carbidopa-levodopa in Neovascular AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Snyder, Robert W., M.D., Ph.D., P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Snyder Biomedical Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Snyder, Robert W., M.D., Ph.D., P.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of&#xD;
      carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of&#xD;
      carbidopa-levodopa in neovascular AMD. This trial is a 9 month extension for patients who&#xD;
      successfully complete protocol 0002 and wish to continue carbidopa-levodopa therapy. It will&#xD;
      use the two higher dose regimens of protocol 0002. these will be assigned according to how&#xD;
      well the higher dose was tolerated in protocol 0002.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This extension will employ the same medications, measurements, guidelines for anti-VEGF&#xD;
      injections and safeguards as in protocol 0002. In combination with protocol 0002, it will&#xD;
      provide a total of 12 months of therapy with carbidopa-levodopa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">July 9, 2020</completion_date>
  <primary_completion_date type="Actual">July 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients who complete 3 months of escalation dose carbidopa-levodopa, will receive 9 additional months of therapy with the highest dose used in protocol 0002, carbidopa-levodopa 25-100 mg 2 tablets TID. If that dose was not well tolerated in study 0002, the patient will receive the intermediate dose, carbidopa-levodopa 25-100 mg, 1 tablet TID.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity by ETDRS visual scale testing</measure>
    <time_frame>From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study (visit 10), a maximum of 9 months.</time_frame>
    <description>Currently refracted, normal light, lines and letters read on the ETDRS chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events experienced by participants during the study</measure>
    <time_frame>Monthly for 9 months</time_frame>
    <description>Adverse events elicited by nonspecific questioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>By OCT, central retinal thickness, in the eye with neovascular AMD</measure>
    <time_frame>From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study (visit 10), a maximum of 9 months.</time_frame>
    <description>Central retinal thickness by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>By OCT, drusen volume in the eye without neovascular AMD</measure>
    <time_frame>From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study, (visit 10), a maximum of 9 months.</time_frame>
    <description>drusen volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Macula; Degeneration</condition>
  <condition>Retina</condition>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carbidopa-levodopa 25-100 mg 2 tablets TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carbidopa-levodopa 25-100 mg 1 tablet TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbidopa-levodopa 25-100 mg</intervention_name>
    <description>High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Intermediate Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completion of Protocol 002.&#xD;
&#xD;
          2. A diagnosis of AMd with choroidal neovascularization (CNV) in 1 eye.&#xD;
&#xD;
          3. Normal or Dry AMD of any grade in the second eye.&#xD;
&#xD;
          4. Age 50-85 years.&#xD;
&#xD;
          5. Willingness to maintain AREDS vitamin Supplements throughout the study, or remain off&#xD;
             of these supplements for the duration of the study, if not taking them prior to the&#xD;
             study.&#xD;
&#xD;
          6. Informed consent at visit 1, which is also Visit 5 of study 002.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Any current use of L-DOPA containing medication or dopamine agonist medication, or any&#xD;
             planned use of any of these agents, except for study medication, during the study;&#xD;
&#xD;
          2. Concurrent use of monoamine oxidase (MAO) inhibitors;&#xD;
&#xD;
          3. Any eye condition, disease, or history of trauma in either eye, which can impair&#xD;
             vision, except cataract or cataract surgery;&#xD;
&#xD;
          4. BCVA worse than 20/60 in the better eye;&#xD;
&#xD;
          5. Wet AMD in the second eye;&#xD;
&#xD;
          6. Neurologic conditions which can impair vision;&#xD;
&#xD;
          7. Parkinson's Disease;&#xD;
&#xD;
          8. Significant orthostatic hypotension, defined as a drop in systolic blood pressure,&#xD;
             immediately upon changing from the supine to standing position, of &gt;19 mmHg, or a&#xD;
             symptomatic drop in systolic blood pressure, immediately upon changing from the supine&#xD;
             to standing position;&#xD;
&#xD;
          9. Significant ECG abnormalities, as judged by the Investigator;&#xD;
&#xD;
         10. Estimated glomerular filtration rate (eGFR) &lt;20 ml/min;&#xD;
&#xD;
         11. Liver enzymes &gt;3 X the upper limit of normal;&#xD;
&#xD;
         12. HbA1C &gt;9.0;&#xD;
&#xD;
         13. Any other significant lab abnormalities, as judged by the Investigator.&#xD;
&#xD;
         14. Women of childbearing potential;&#xD;
&#xD;
         15. Known retinal hemorrhage;&#xD;
&#xD;
         16. Subjects who are not fluent in English.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Robert W Snyder, MD, PhD, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

